Fenwick & West and Wilson Sonsini Goodrich & Rosati advised Metagenomi on the deal while Gunderson Dettmer represented PFM Health Sciences. Metagenomi, a genetic medicines company […]
Metagenomi’s $175 Million Series B Financing
ABL Bio’s License Agreement with SANOFI
Wilson Sonsini Goodrich & Rosati advised ABL on the deal. ABL Bio, Inc., a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced […]
Ambagon Therapeutics’ $85 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Ambagon Therapeutics on the deal. Ambagon Therapeutics, a biotechnology company unlocking intrinsically disordered proteins and other difficult-to-target protein classes, announced […]
Adanate’s $30 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Adanate on the deal. Adanate, a biotech company focusing on therapies in oncology and immunology, recently raised $30 million in […]
Sorriso Pharmaceuticals’ $31 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Sorriso Pharmaceuticals on the deal. Sorriso Pharmaceuticals, a biotechnology company advancing a pipeline of disease-modifying antibodies for the treatment of […]
Metagenomi’s Collaboration with Moderna
Fenwick & West and Wilson Sonsini Goodrich & Rosati represented Metagenomi on the deal. Metagenomi, Inc., a genetic medicines company with a versatile portfolio of next-generation […]
Ventyx’s $174 Million IPO
Wilson Sonsini Goodrich & Rosati advised Ventyx on the deal. Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living […]
Quanta Therapeutics’ $60 Million Series C Financing Round
Wilson Sonsini Goodrich & Rosati advised Quanta Therapeutics on the deal. Quanta Therapeutics, Inc., a privately held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancer […]
CinCor Pharma’s $143 Million Series B Financing
Wilson Sonsini Goodrich & Rosati represented General Atlantic on the transaction. CinCor Pharma, Inc. announced the completion of a $143 million Series B financing. The financing […]
BIOMILQ, Inc.’s $21 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the deal. North Carolina-based mammary biotechnology company BIOMILQ, Inc., announced the successful close of $21 million in […]
Crinetics’ Launch of Radionetics Oncology
Wilson Sonsini Goodrich & Rosati advised Crinetics on the deal. Crinetics Pharmaceuticals, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel […]
858 Therapeutics’ $60 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised New Enterprise Associates (NEA) and Versant Ventures on the deal. 858 Therapeutics announced the completion of a $60 million Series […]